Financials in USD. Standardized financial statements.
A compact view of how Medite Cancer Diagnostics, Inc. turns revenue into operating income and net income.
| Metric | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|
| Revenue? | $6.81M | $9.24M | $9.89M |
| Revenue Growth? | -26.3% | -6.6% | 0.0% |
| Cost of Revenue? | $6.94M | $5.82M | $6.26M |
| Gross Profit? | -$131,000 | $3.42M | $3.63M |
| Gross Margin? | -1.9% | +37.0% | +36.7% |
| Operating Expenses? | $6.35M | $5.08M | $4.22M |
| Operating Income? | -$6.48M | -$1.66M | -$599,000 |
| EBITDA? | -$6.19M | -$1.45M | -$422,000 |
| Income Before Tax | -$7.30M | -$2.29M | -$781,000 |
| Income Tax Expense | -$487,000 | -$132,000 | $78,000 |
| Net Income? | -$6.81M | -$2.16M | -$859,000 |
| EPS? | $-0.26 | $-0.10 | $-0.04 |
| Diluted EPS? | $-0.26 | $-0.10 | $-0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality